5-MEO DMT
5-MEO DMT is short duration, high power Connection Supplement. It is found in the secretion of the parotoid glands of the Bufo alvarius toad. Inhalation of vapor from toad secretion containing 5-MeO-DMT has become popular in naturalistic settings as a treatment of mental health problems or as a means for spiritual exploration.
List of Connection Supplements
Connection Supplement > 5-MEO DMT, Ayahuasca, Cannabis, Chloroform, DMT, Datura, Haoma, Kaneh Bosm, Kava, Ketamine, Kykeon, LSD, MDMA, Maikua, Manna, Nitrous Oxide, Peyote, Psilocybin Mushroom, Santa Rosa, Soma, Tobacco, Yaqona
Related LP Terms
Connection Supplement > Connection Axes, Connection Coach, Connection Companion, Connection Therapy, Crown Stupifier, Disjuncture
Related Terms
Connection Supplement > Albert Hofmann, Womb Room
Notes
5-MEO DMT acts as a serotonin 5-HT-1-A/5-HT-2A/C receptor agonist and induces a diversity of subjective effects, including auditory, visual, and time perception distortions, emotional experiences, and memory impairment that vary depending on the dose and route of administration [3].
Recent studies have suggested that 5-MeO-DMT may have psychotherapeutic effects and may enhance mood in general or may be particularly mood enhancing for those experiencing clinically significant negative affect [2][4][5].
A single inhalation of 5-MeO-DMT in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.[1]
Speck Sheet - https://thethirdwave.co/psychedelics/5-meo-dmt/
Enhancements
Affective
Cognitive
Creative
Empathic
Cognitive
Anecdotes
Footnotes
- ↑ Uthaug, M. V., R. Lancelotta, K. van Oorsouw, K. P. C. Kuypers, N. Mason, J. Rak, A. Šuláková, et al. “A Single Inhalation of Vapor from Dried Toad Secretion Containing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) in a Naturalistic Setting Is Related to Sustained Enhancement of Satisfaction with Life, Mindfulness-Related Capacities, and a Decrement of Psychopathological Symptoms.” Psychopharmacology 236, no. 9 (September 2019): 2653–66. https://doi.org/10.1007/s00213-019-05236-w.